Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 79

1.

New selective inhibitors of MMP-13 for inflammatory diseases: a patent evaluation (W02012151158).

Li NG, Tang YP, Duan JA.

Expert Opin Ther Pat. 2013 May;23(5):669-75. doi: 10.1517/13543776.2013.779254. Epub 2013 Mar 19.

PMID:
23506002
2.

Matrix metalloproteinase inhibitors: a patent review (2011 - 2013).

Li NG, Tang YP, Duan JA, Shi ZH.

Expert Opin Ther Pat. 2014 Sep;24(9):1039-52. doi: 10.1517/13543776.2014.937424. Epub 2014 Aug 6. Review.

PMID:
25098768
3.

Identification of matrix metalloproteinase inhibitors by chemical arrays.

Kawatani M, Fukushima Y, Kondoh Y, Honda K, Sekine T, Yamaguchi Y, Taniguchi N, Osada H.

Biosci Biotechnol Biochem. 2015;79(10):1597-602. doi: 10.1080/09168451.2015.1045829. Epub 2015 May 19.

PMID:
25988721
4.

Cheminformatics-based drug design approach for identification of inhibitors targeting the characteristic residues of MMP-13 hemopexin domain.

Kothapalli R, Khan AM, Basappa, Gopalsamy A, Chong YS, Annamalai L.

PLoS One. 2010 Aug 31;5(8):e12494. doi: 10.1371/journal.pone.0012494.

5.

In silico study combining docking and QSAR methods on a series of matrix metalloproteinase 13 inhibitors.

Xi L, Li S, Yao X, Wei Y, Li J, Liu H, Wu X.

Arch Pharm (Weinheim). 2014 Nov;347(11):825-33. doi: 10.1002/ardp.201400200. Epub 2014 Sep 2.

PMID:
25363411
6.

Design, synthesis and evaluation of novel metalloproteinase inhibitors based on L-tyrosine scaffold.

Cheng XC, Wang RL, Dong ZK, Li J, Li YY, Li RR.

Bioorg Med Chem. 2012 Oct 1;20(19):5738-44. doi: 10.1016/j.bmc.2012.08.014. Epub 2012 Aug 22.

PMID:
22967811
7.

Recent Research Advances in Selective Matrix Metalloproteinase-13 Inhibitors as Anti-Osteoarthritis Agents.

Xie XW, Wan RZ, Liu ZP.

ChemMedChem. 2017 Aug 8;12(15):1157-1168. doi: 10.1002/cmdc.201700349. Epub 2017 Jul 19. Review.

PMID:
28722301
8.

Synthesis of derivatives of methyl rosmarinate and their inhibitory activities against matrix metalloproteinase-1 (MMP-1).

Yuan H, Lu W, Wang L, Shan L, Li H, Huang J, Sun Q, Zhang W.

Eur J Med Chem. 2013 Apr;62:148-57. doi: 10.1016/j.ejmech.2012.09.047. Epub 2012 Oct 16.

PMID:
23353736
9.

Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment.

Ribbens C, Martin y Porras M, Franchimont N, Kaiser MJ, Jaspar JM, Damas P, Houssiau FA, Malaise MG.

Ann Rheum Dis. 2002 Feb;61(2):161-6.

10.

Discovery of novel, highly potent, and selective quinazoline-2-carboxamide-based matrix metalloproteinase (MMP)-13 inhibitors without a zinc binding group using a structure-based design approach.

Nara H, Sato K, Naito T, Mototani H, Oki H, Yamamoto Y, Kuno H, Santou T, Kanzaki N, Terauchi J, Uchikawa O, Kori M.

J Med Chem. 2014 Nov 13;57(21):8886-902. doi: 10.1021/jm500981k. Epub 2014 Oct 15.

PMID:
25264600
11.

Structure-Based Design and Synthesis of Potent and Selective Matrix Metalloproteinase 13 Inhibitors.

Choi JY, Fuerst R, Knapinska AM, Taylor AB, Smith L, Cao X, Hart PJ, Fields GB, Roush WR.

J Med Chem. 2017 Jul 13;60(13):5816-5825. doi: 10.1021/acs.jmedchem.7b00514. Epub 2017 Jun 27.

PMID:
28653849
13.

In vivo imaging of matrix metalloproteinase 12 and matrix metalloproteinase 13 activities in the mouse model of collagen-induced arthritis.

Lim NH, Meinjohanns E, Bou-Gharios G, Gompels LL, Nuti E, Rossello A, Devel L, Dive V, Meldal M, Nagase H.

Arthritis Rheumatol. 2014 Mar;66(3):589-98. doi: 10.1002/art.38295.

14.

Non-Zinc-Binding Inhibitors of MMP-13: GRID-Based Approaches to Rationalize the Binding Process.

Di Pizio A, Agamennone M, Tortorella P.

Curr Top Med Chem. 2016;16(4):449-59. Review.

PMID:
26268339
15.

Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhibitors.

Nuti E, Panelli L, Casalini F, Avramova SI, Orlandini E, Santamaria S, Nencetti S, Tuccinardi T, Martinelli A, Cercignani G, D'Amelio N, Maiocchi A, Uggeri F, Rossello A.

J Med Chem. 2009 Oct 22;52(20):6347-61. doi: 10.1021/jm900335a.

PMID:
19775099
16.

Thieno[2,3-d]pyrimidine-2-carboxamides bearing a carboxybenzene group at 5-position: highly potent, selective, and orally available MMP-13 inhibitors interacting with the S1″ binding site.

Nara H, Sato K, Naito T, Mototani H, Oki H, Yamamoto Y, Kuno H, Santou T, Kanzaki N, Terauchi J, Uchikawa O, Kori M.

Bioorg Med Chem. 2014 Oct 1;22(19):5487-505. doi: 10.1016/j.bmc.2014.07.025. Epub 2014 Aug 7.

PMID:
25192810
17.

Synthesis and structure-activity relationship analysis of caffeic acid amides as selective matrix metalloproteinase inhibitors.

Shi ZH, Li NG, Shi QP, Tang H, Tang YP, Li W, Yin L, Yang JP, Duan JA.

Bioorg Med Chem Lett. 2013 Mar 1;23(5):1206-11. doi: 10.1016/j.bmcl.2013.01.027. Epub 2013 Jan 16.

PMID:
23375794
18.

5-Arylidene-4-thiazolidinone derivatives active as antidegenerative agents on human chondrocyte cultures.

Panico A, Maccari R, Cardile V, Crasci L, Ronsisvalle S, Ottanà R.

Med Chem. 2013 Feb;9(1):84-90.

PMID:
22762165
19.

Fragment-Based Discovery of 5-Arylisatin-Based Inhibitors of Matrix Metalloproteinases 2 and 13.

Agamennone M, Belov DS, Laghezza A, Ivanov VN, Novoselov AM, Andreev IA, Ratmanova NK, Altieri A, Tortorella P, Kurkin AV.

ChemMedChem. 2016 Sep 6;11(17):1892-8. doi: 10.1002/cmdc.201600266. Epub 2016 Jul 15.

PMID:
27418256
20.

A new class of potent matrix metalloproteinase 13 inhibitors for potential treatment of osteoarthritis: Evidence of histologic and clinical efficacy without musculoskeletal toxicity in rat models.

Baragi VM, Becher G, Bendele AM, Biesinger R, Bluhm H, Boer J, Deng H, Dodd R, Essers M, Feuerstein T, Gallagher BM Jr, Gege C, Hochgürtel M, Hofmann M, Jaworski A, Jin L, Kiely A, Korniski B, Kroth H, Nix D, Nolte B, Piecha D, Powers TS, Richter F, Schneider M, Steeneck C, Sucholeiki I, Taveras A, Timmermann A, Van Veldhuizen J, Weik J, Wu X, Xia B.

Arthritis Rheum. 2009 Jul;60(7):2008-18. doi: 10.1002/art.24629.

Supplemental Content

Support Center